Evosheld

[kitchengardener2]

This is an interesting article about Evosheld and take up figures.

Wouldn't have to ask me twice!!

chemistryworld.com/news/pro...

[Ellim]

Nor me, this country is so far behind on drugs for the immunosuppressed that god knows when we will able to get it.

[sandybeaches]

Perhaps the drug being so restricted in Canada is one reason why the demand for Evusheld is so low. I find it hard to believe it is because patients do not want it.Also, if a double dose, as recommended in the USA now, would be adopted it would be more effective against the BA5 strain.

It boggles my mind that it would not be given to all CLL patients as the cost is lower than a day as an in patient is hospital is more.

Sandy Beaches

West Coast, Canada

[kitchengardener2 in reply to sandybeaches]

My feeling exactly!

[Retiredman in reply to sandybeaches]

I have NHL and currently am doing well with Imbruvica. I have had the J&J vaccine but my doctors don't like the mRNA stuff. I got my Evusheld shots back in March of 2022 here in the United States. Two shots three weeks apart. I was told it was good for about 6 months. I saw my Oncologist two weeks ago and asked if could take the shot again. I was told NO because the FDA has not decided that a second round of shots would be appropriate because of a lack of data. No shortage of the drug here. Totally confused on their logic! So, it was safe to give me the shots once but not twice? I have total trust in my doctors, they are great. I have almost no confidence in the FDA or the CDC and their motives. Good Luck.

[Shooey]

Me neither!!Just don’t understand why they can’t get their heads round the fact that the cost of being proactive is considerably less than the cost of being reactive. I just don’t buy the current excuses for not authorising it. I have relatives traveling to the US next month and they offered to bring the drug back for me, unfortunately my GP confirmed that I wouldn’t get a health professional to administer it. So, another long winter mostly spent in hibernation.

Shooey

[kitchengardener2 in reply to Shooey]

I like the idea but until it is approved here I think you maybe get into trouble if you imported it. Best to wait.

[bennevisplace in reply to Shooey]

Even if you could persuade a nurse to jab you in the buttocks on the quiet, keeping the drug within temperature range might prove too difficult "...needs to be refrigerated and stored at temperatures of 2-8 degrees Celsius. Couriered drug needs to maintain the cold chain upon arrival. ... pre-drawn syringes can be stored at up to 25 degrees Celsius for up to 4 hours".

[Shooey in reply to bennevisplace]

Thanks for the clarification. I guess by the time they get around to reviewing it next spring Omicron will have virtually disappeared and BA5 may well not be the dominant variant as it is now so it could well be obsolete anyway, unless they can adapt.

[bennevisplace in reply to Shooey]

Indeed yes. Sending Evusheld to NICE for review is equivalent to keeping the Forth rail bridge closed until the paint job is finished.

[Shooey in reply to bennevisplace]

Good analogy!!

[bennevisplace]

Thanks for posting this.

Re the statement by a spokesman for the UK HSA: ‘We have been conducting an assessment of Evusheld, which includes asking clinicians to advise on the most appropriate option for the NHS in line with all available data.’ If it's a genuine quote it doesn't sound like they have been doing any serious work. There's no record of an assessment of Evusheld on the HSA website, and they have published nothing.

[Kbcjones]

I'll say it again - it did absolutely nothing for me. I was sick for almost three weeks. So if you get it, don't bank on it.

[LeoPa]

2 days ago there was another one saying the cdc doesn't recommend it anymore.Go figure.

[Justasheet1 in reply to LeoPa]

Leo,

Who doesn’t recommend it?

Jeff

Per the CDC:

“COVID-19 MENU

Pre-exposure Prophylaxis

Updated Sept. 2, 2022

Pre-exposure prophylaxis for COVID-19 for those who are moderately to severely immunocompromised

What You Need To Know

In addition to following the recommended COVID-19 vaccination schedule, tixagevimab/cilgavimab (Evusheld), a combination of two monoclonal antibodies, should be administered to people who are moderately or severely immunocompromised every 6 months for pre-exposure prophylaxis to supplement vaccine protection.

Per the product EUA, Evusheld can be given at least 2 weeks after COVID-19 vaccine. People may initiate Evusheld at any time after this interval, including between doses in the primary series and between any primary and booster doses.

This medication can provide protection for those not expected to mount an adequate immune response following vaccination, including those who are immunocompromised due to a medical condition or immunosuppressive medication, or for those individuals for whom COVID-19 vaccination is not recommended due to a history of severe adverse reaction to COVID-19 vaccination.

Evusheld is administered by intramuscular injection by a healthcare provider at an office or healthcare facility.

Current locations of EVUSHELD distribution can be found here.

The current treatment guidelines [5.4 MB, 456 pages] on the use of Evusheld as pre-exposure prophylaxis:

Tixagevimab 300 mg plus cilgavimab 300 mg (Evusheld) administered as two 3-mL intramuscular (IM) injections for adults and adolescents (aged ≥12 years and weighing ≥40 kg) who do not have SARS-CoV-2 infection, who have not been recently exposed to an individual with SARS-CoV-2 infection AND who:

Are moderately to severely immunocompromised or

Are not able to be fully vaccinated with any available COVID-19 vaccines due to history of severe adverse reactions

Tixagevimab plus cilgavimab should be repeated every 6 months.

Individuals who received tixagevimab 150 mg plus cilgavimab 150 mg should be given a second dose as soon as possible.

If the initial dose was administered ≤3 months prior, the second dose should be tixagevimab 150 mg plus cilgavimab 150 mg.

If the initial dose was administered >3 months prior, the second dose should be tixagevimab 300 mg plus cilgavimab 300 mg.

Individuals should be clinically monitored after injections and observed for at least 1 hour.

Evusheld is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to Evusheld.

There is not currently sufficient evidence to recommend either for or against the use of SARS-CoV-2 serologic testing to assess for immunity or guide clinical decisions about using Evusheld for pre-exposure prophylaxis. For more information, see NIH’s COVID-19 Treatment Guidelines.

Evusheld and timing with COVID-19 vaccination

Evusheld may be given at least 2 weeks after any COVID-19 vaccine.

After this interval, Evusheld may be initiated at any time between primary series and booster doses.

COVID-19 vaccines may be administered at any time after Evusheld administration.

Use of monoclonal antibodies is not a substitute for COVID-19 vaccination.

Last Updated Sept. 2, 2022”

[LeoPa in reply to Justasheet1]

bccdc.ca/Health-Professiona...

[LeoPa in reply to Justasheet1]

healthunlocked.com/cllsuppo....

[Justasheet1 in reply to LeoPa]

Leo,

You meant then the bccdc and not the

us-cdc?

Jeff

[LeoPa in reply to Justasheet1]

Looks like. I never noticed the difference 😞

[kimiD]

This graphic is from the latest US CDC update on 9/2/22.

CDC graphic